How long population immunity induced by natural infection, primary-series vaccination, and booster vaccination against SARS-CoV-2 lasts?
A new study from Qatar offers some clues. 1/
Using a test-negative study design,
population immunity against infection of each of previous infection, primary-series vaccination, and booster vaccination were characterized at the national level month by month for 2 calendar years 2/
The 3 forms of population immunity showed rapid variation over time driven by waning of protection. Vaccine-derived population immunity declined by 1 absolute percentage point every 5 days! 3/
Omicron introduction immensely reduced the three forms of population immunity within one month by about 50 absolute percentage points. 4/
Previous-infection effectiveness against reinfection was strong before Omicron, but declined with time after a wave & rebounded after a new wave. Effectiveness dropped immediately after Omicron emergence from 88.3% in November 2021 to 51.0% in December 2021. 5/
Primary-series VE against infection was 84.0% in April 21, soon after introduction, before waning gradually to 52.7% by Nov’ 21.
VE declined linearly by ~1% point every 5 days. After Omicron, VE dropped suddenly from 52.7% in Nov 2021 to negligible levels in Dec 21. 6/
Booster effectiveness dropped immediately after Omicron emergence from 83.0% in November 2021 to 32.9% in December 2021, and continued to decline thereafter. 7/
Effectiveness of previous infection and vaccination against severe, critical, or fatal COVID-19 were generally >80% throughout the study duration. 8/
Takeaways:
1-Both previous-infection and vaccine population immunities vary rapidly at a national level creating fertile grounds for repeated waves of infection to occur even within months of each other. 9/
2-High levels of population immunity may not be sustained for more than a year or so.
3-So, preventing infection/reinfection, transmission, or future waves of infection cannot sustainably be done with current vaccines nor by the entire population being infected. 10/
4-Timely administration of boosters for those vulnerable to severe COVID-19 may remain essential for years to come.
5-Repeated waves of infection may also facilitate further evolution of the virus and continual immune evasion. 11/
6-Emergence of a new variant that is substantially different from circulating
variants can suddenly and immensely reduce population immunity leading to large epidemic wave. 12/
7-However, the durability of population immunity against severe COVID-19 will likely curtail the severity of future waves. 13/13
A plethora of respiratory viruses, including SARS-CoV-2, strategically manipulate the host's splicing machinery to circumvent antiviral responses. 1/
What is RNA splicing? ....a form of RNA processing in which a newly made precursor messenger RNA (pre-mRNA) transcript is transformed into a mature messenger RNA (mRNA). During splicing, introns (non-coding regions) are removed, & exons (coding regions) are joined together 2/
According to a new study, SARS-CoV-2 exploits the host splicing machinery to bolster viral replication & subvert the immune response by selectively upregulating unproductive splicing isoforms from antigen presentation & antiviral response genes. 3/
When is the Indian Covid surge driven by XBB.1.16 going to peak?
Y’day India reported >7500 cases. Early trends point the tally would def cross 8500 today. However, there is a lot of speculations on when the current peak of the surge would peak. Let’s look for the answers 1/
There are three different views:
1-According to @JPWeiland as far as weekly growth is concerned, it is already peaked. But the outbreak is still growing & the positivity rate is at the highest since Jan’21 BA.2 peak! 2/
2-As per the @MoHFW_INDIA’s ‘unusual’ claim, the COVID in India is moving towards the endemic stage. They expect the cases to rise for the next 10-12 days, and will gradually come down to become endemic 3/
I remember during my ppts for IAP’s ‘Mission Cowin’ I used to refer ORF8 an accessory protein of SARS2 that mediates immune evasion through down-regulating MHC-I 2/
ORF8 gained recognition in SARS-CoV-2 pathogenesis due to its hypervariability, secretory property, and unique structure.
Some recent papers even today describe its pivotal roles in both viral replication & immune evasion. 3/
A new study isolated two human antibodies, 12-16 & 12-19, which neutralise all SARS-CoV-2 variants tested (including XBB.1.5.). They also blocked infection in hamsters w/ BA.1 intranasally.
The fig characterises in vitro & in vivo potency and breadth of these two mAbs 1/
Structural analyses revealed both Abs targeted a conserved epitope located at the interface between NTD & subdomain 1, revealing a previously unrecognized site of vulnerability on SARS2 spike.
Antibodies 12-16 and 12-19 target a quaternary epitope between SD1 and NTD 2/
Interestingly, these Abs prevent viral receptor engagement by locking the RBD of spike in down conformation, revealing a novel mechanism of virus neutralization for non-RBD Abs. Antibody binding is incompatible w/ RBD-up state, suggesting antibody is “locked” in a down state. 3/
It has been a month when @siamosolocani 1st flagged this variant. Later, I started tracking it. We are still amid an ongoing surge, it’s time to take a stock of the situation: what we do know, what we don’t 1/
1-XBB.1.16 has succeeded in creating a new, significant surge in India after a gap of >6 months. A feat that even BA.5, BQ.1 & XBB.1.5 failed to achieve! 2/
2-XBB.1.16 definitely has got a growth advantage & more fitter than other circulating XBBs & has even replaced some other similar sublineages like XBB.1.5 & XBB.1.9 3/ @vinodscaria